Stock Performance and Price Targets - Shares of Arcutis Biotherapeutics (ARQT) have gained 34.5% over the past four weeks, closing at $11.51 [1] - The mean price target from Wall Street analysts is $18.43, indicating a potential upside of 60.1% [1] - The average price target ranges from $11 to $26, with a standard deviation of $4.50, reflecting variability in analyst estimates [2] - The most optimistic price target suggests a 125.9% upside, while the lowest estimate indicates a 4.4% decline from the current price [2] Analyst Consensus and Earnings Revisions - Strong agreement among analysts about ARQT's ability to report better earnings strengthens the view of potential upside [4] - Three earnings estimates have been revised higher over the last 30 days, with no negative revisions, leading to a 16.3% increase in the Zacks Consensus Estimate [10] - ARQT currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [11] Limitations of Price Targets - Price targets are often misleading and rarely indicate where a stock's price is actually heading, according to empirical research [5] - Analysts may set overly optimistic price targets to generate interest in stocks, influenced by business incentives [6] - A low standard deviation in price targets indicates high agreement among analysts but does not guarantee the stock will hit the average target [7] Investment Considerations - While price targets should not be ignored, investment decisions based solely on them could lead to disappointing returns [8] - The direction of price movement implied by consensus targets appears to be a good guide, even if the exact target is unreliable [12]

Technical Analysis - ARQT surpassed resistance at the 50-day moving average, indicating a short-term bullish trend [1] - The 50-day simple moving average is a key technical indicator used to determine support or resistance levels [1] - ARQT has moved 21% higher over the last four weeks, suggesting potential for another rally [2] Earnings and Revisions - ARQT has seen 3 upward earnings estimate revisions for the current fiscal year with no downward revisions [2] - The consensus earnings estimate for ARQT has moved up, reinforcing the bullish outlook [2] Investment Consideration - ARQT is currently a Zacks Rank 2 (Buy) stock, indicating positive sentiment [2] - The combination of technical indicators and positive earnings revisions makes ARQT a stock to watch [3]

Technical Analysis - ARQT recently surpassed the 200-day moving average, indicating a long-term bullish trend [1] - The 200-day moving average is a widely-used indicator for establishing long-term market trends [2] - ARQT shares have increased by 21% over the past four weeks [2] Earnings and Revisions - ARQT has seen positive earnings estimate revisions, with no lower estimates in the past two months [3] - Three higher estimates have been made for the current fiscal year, and the consensus estimate has also increased [3] Investment Potential - ARQT is currently rated as a Zacks Rank 2 (Buy) stock, suggesting potential for continued growth [2] - The combination of positive earnings revisions and technical indicators supports a bullish outlook for ARQT [3]

Technical Analysis - A hammer chart pattern has formed in Arcutis Biotherapeutics' last trading session, indicating a potential trend reversal as bulls counteract bears to find support [1] - The hammer pattern is a technical indication of nearing a bottom with likely subsiding of selling pressure, signaling that bears might have lost control over the price [1][2] - Hammer candles can occur on any timeframe and are utilized by both short-term and long-term investors, but should be used in conjunction with other bullish indicators [2] Fundamental Analysis - Wall Street analysts have shown strong agreement in raising earnings estimates for Arcutis Biotherapeutics, enhancing its prospects of a trend reversal [1] - The consensus EPS estimate for the current year has increased 14.5% over the last 30 days, indicating that analysts expect better earnings than previously predicted [3] - Arcutis Biotherapeutics currently has a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 stocks ranked based on earnings estimate revisions and EPS surprises [3] Market Performance - Arcutis Biotherapeutics' stock has lost 13% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal [1] - Stocks with a Zacks Rank 1 or 2, such as Arcutis Biotherapeutics, usually outperform the market, further supporting the likelihood of a trend reversal [3]

Technical Analysis - ARQT reached a significant support level and broke through the 20-day moving average, indicating a short-term bullish trend [1] - The 20-day simple moving average is a useful tool for short-term traders as it smooths out price trends and provides trend reversal signals [2] - ARQT's price moved above the 20-day SMA (9.22) to 9.26, suggesting a positive trend [3] - ARQT's stock price increased by 13.5% over the last four weeks, potentially signaling another rally [3] Earnings and Revisions - ARQT has seen 3 upward earnings estimate revisions for the current fiscal year with no downward revisions, strengthening the bullish case [4] - The consensus estimate for ARQT has also moved higher, indicating positive sentiment among analysts [4] Investment Outlook - ARQT is currently a Zacks Rank 2 (Buy) stock, further supporting its potential for near-term gains [3] - Investors may consider ARQT for potential gains due to its technical levels and positive earnings estimate revisions [4]

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $10.82, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.43 indicates a 70.3% upside potential.The average comprises seven short-term price targets ranging from a low of $11 to a high of $26, with a standard deviation of $4.50. While the lowest estimate indicates an increase of 1.7% from the cu ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Serge Belanger - Needham & Co. Kambiz Yazdi - Jeff ...

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.43%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.42, delivering a surprise of 12.50%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or O ...